ASCO
Pharma reveals its ASCO presentation data
May 12, 2015Research and Development, Sales and Marketing ASCO, AZ, AbbVie, Roche, chicago, data
AstraZeneca, Genentech and AbbVie have all revealed which cancer drugs they will show data for at The American Society of …
Pfizer breast cancer trial stopped following promising results
April 15, 2015Sales and Marketing ASCO, FDA, Pfizer, ibrance, palbociclib
Regulators have stopped a Phase III clinical trial of Pfizer’s Ibrance early after it demonstrated improved survival in women with …
Merck and Advaxis team up on immuno-oncology
August 26, 2014Manufacturing and Production, Medical Communications, Research and Development ASCO, Merck, immunology, pd-1, pembrolizumab
Advaxis and Merck have signed a research deal to investigational Merck’s PD-1 inhibitor pembrolizumab in combination with Advaxis’ listeria-based cancer …
PD-1 cancer race heats up as Merck takes lead
July 2, 2014Research and Development, Sales and Marketing ASCO, Cancer, Merck, melanoma, mk3475, oncology, pembrolizumab
Merck’s oncology drug pembrolizumab has taken a big step towards becoming Europe’s first PD-1 cancer treatment as the EMA accepts …
Value tops the agenda at ASCO cancer conference
June 30, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ASCO, Cancer, chicago, mccafferty, oncology
The annual American Society of Clinical Oncology (ASCO) meeting has long been one of the most important events on the …
New BMS cancer treatment shines
June 25, 2014Research and Development, Sales and Marketing ASCO, BMS, Cancer, Yervoy, braf, melanoma, nivolumab
Bristol-Myers Squibb’s investigational cancer treatment nivolumab has helped patients with the deadliest form of skin cancer to live longer. The …
Merck drug shines at ASCO
June 4, 2014Research and Development, Sales and Marketing ASCO, Cancer, FDA, MK-3475, Merck, melanoma
Merck has shown off one of its investigative cancer drug’s impressive results in advanced head and neck cancer at ASCO …
Boehringer lung cancer drug shows survival benefit
June 3, 2014Sales and Marketing ASCO, Boehringer, NSCLC, afatinib, giotrif, lung cancer
A new analysis of two late-stage trials shows that Boehringer drug Giotrif extends overall survival in a large proportion of …
ASCO 2014: old dogs, new tricks top the bill
June 2, 2014Research and Development, Sales and Marketing ASCO, Cancer, chicago, docetaxel, exemestane
Research showing the effectiveness of established cancer treatments in new settings is taking centre stage at this year’s American Society …
BMS signs cancer deal
May 28, 2014Research and Development, Sales and Marketing ASCO, AstraZeneca, BMS, Cancer, Merck, Roche, cytomx, oncology
Bristol-Myers Squibb has partnered with CytomX Therapeutics to discover and develop new immuno-oncology candidates using the latter’s Probody Platform technology. …
Roche gets oncology boost with cancer vaccine
May 16, 2014Research and Development, Sales and Marketing ASCO, Roche, bladder cancer, oncology
Roche’s most advanced experimental cancer immunotherapy has had impressive results in a small Phase I trial, reducing tumour size in …
AstraZeneca lung cancer data reveals promise
May 15, 2014Sales and Marketing ASCO, AstraZeneca, NSCLC, azd0291, lung cancer
AstraZeneca has released promising data in a lung cancer trial with one of its investigational drugs, AZD9291, which has breakthrough …
US cancer docs warn of rising drug prices
May 7, 2014Research and Development, Sales and Marketing ASCO, Cancer, NICE, Obama, US, United States, republicans
American cancer doctors are warning that the rising price of oncology medicines is making it unaffordable for the country’s healthcare …
ASCO: Dispatches from the frontline against cancer
July 22, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ASCO, McConaghie
The growing promise of pharma’s immunotherapy pipeline for cancer was undoubtedly the hottest topic at this year’s ASCO conference. The …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
